Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
QuintilesIMS
Teva
Argus Health
US Army
UBS
Cantor Fitzgerald
McKinsey

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,861,076

« Back to Dashboard

Which drugs does patent 6,861,076 protect, and when does it expire?

Patent 6,861,076 protects TRISENOX and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.
Summary for Patent: 6,861,076
Title: Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract:The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Application Number:10/758,994
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,861,076

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL) ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-002 Oct 13, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,861,076

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,855,339 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
6,884,439 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
6,982,096 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
6,723,351 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,861,076

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1397399 ➤ Try a Free Trial
Australia 2002300339 ➤ Try a Free Trial
Australia 747474 ➤ Try a Free Trial
Brazil 9814857 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Moodys
Chubb
Baxter
Federal Trade Commission
Covington
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.